Squarepoint
ALMR

Squarepoint’s Alamar Biosciences ALMR Stock Holding History

Squarepoint’s Portfolio ALMR Stock Details ALMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283K Buy
+10,460
New +$237K ﹤0.01% 3851

Other funds holding ALMR

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Squarepoint's ALMR Position: Q2 2026 in Review

Squarepoint opened a new position in Alamar Biosciences (ALMR) in Q2 2026: 10,460 shares worth $283K. The stake represents ﹤0.01% of the portfolio and ranks #3851 among its holdings.

86 funds tracked by Wall St. Rank hold ALMR as of Q2 2026.

  • Squarepoint held 10,460 shares of Alamar Biosciences worth $283K as of Q2 2026.
  • Alamar Biosciences was a new Squarepoint position in Q2 2026.
  • Alamar Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3851 holding.
  • 86 funds tracked by Wall St. Rank held Alamar Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.